crizanlizumab
novartis
['crizanlizumab']
dr alan anderson - interim spartan study analysis - crizanlizumab for priapism in scd 71% of patients with reduction in episodes and 53% reduction on average. 62% reduction in patients on it over 22 weeks #ash2022 #conquerscd 
Hematologist. The views expressed here are my own.